The Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study for Patients on a Direct Oral Anticoagulant Who Need an Elective Surgery or Procedure: Design and Rationale

Thrombosis and Haemostasis

Volumn 117, Issue 12, 2017, Pages 2415-2424

  Douketis, James D ^a   Spyropoulos, Alex C ^b   Anderson, Julia M ^c   Arnold, Donald M ^a   Bates, Shannon M ^a   Blostein, Mark ^d   Carrier, Marc ^e   Caprini, Joseph A ^f   Clark, Nathan P ^g   Coppens, Michiel ^h   Dentali, Francesco ⁱ   Duncan, Joanne ^a   Gross, Peter L ^a   Kassis, Jeannine ^j   Kowalski, Stephen ^k   Lee, Agnes Y ^l   Le Gal, Gregoire ^m   Le Templier, Geneviève ⁿ   Li, Na ^a   MacKay, Elizabeth ^o   Shah, Vinay ^p   Shivakumar, Sudeep ^q   Solymoss, Susan ^d   Spencer, Frederick A ^a   Syed, Summer ^a   Tafur, Alfonso J ^f   Vanassche, Thomas ^r   Thiele, Thomas ^s   Wu, Cynthia ^t   Yeo, Erik ^u   Schulman, Sam ^a   more..

^a MCMASTER UNIVERSITY   (Canada)

^b LENOX HILL HOSPITAL   (United States)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

^d MCGILL UNIVERSITY   (Canada)

^e OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^f NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^g KAISER PERMANENTE   (United States)

^h UNIVERSITY OF AMSTERDAM   (Netherlands)

ⁱ UNIVERSITY OF INSUBRIA   (Italy)

^j UNIVERSITÉ DE MONTRÉAL   (Canada)

^k UNIVERSITY OF MANITOBA   (Canada)

^l UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^m INSTITUT DU SAVOIR MONTFORT   (Canada)

ⁿ CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

^o UNIVERSITY OF CALGARY   (Canada)

^p HENRY FORD HOSPITAL   (United States)

^q DALHOUSIE UNIVERSITY   (Canada)

^r UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^s UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^t UNIVERSITY OF ALBERTA   (Canada)

^u UNIVERSITY OF TORONTO   (Canada)

more..

Author keywords

clinical trials; oral anticoagulants; surgery; thrombosis

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; DIRECT ORAL ANTICOAGULANT; RIVAROXABAN; UNCLASSIFIED DRUG; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

ACTIVATED PARTIAL THROMBOPLASTIN TIME; ANTICOAGULATION; ARTERIAL THROMBOEMBOLISM; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; CLINICAL OUTCOME; CLINICAL PRACTICE; COGNITIVE DEFECT; CREATININE CLEARANCE; ELECTIVE SURGERY; FOLLOW UP; KIDNEY FUNCTION; MENTAL DISEASE; PATIENT CARE; PERIOPERATIVE ANTICOAGULANT USE FOR SURGERY EVALUATION; PRIORITY JOURNAL; SAMPLE SIZE; THROMBIN TIME; THROMBOEMBOLISM; ADULT; CANADA; COHORT ANALYSIS; FEMALE; HEART SURGERY; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PERIOPERATIVE PERIOD; PERSONALIZED MEDICINE; POSTOPERATIVE COMPLICATION; PROSPECTIVE STUDY;

ADMINISTRATION, ORAL; ADULT; ANTICOAGULANTS; ATRIAL FIBRILLATION; CANADA; CARDIAC SURGICAL PROCEDURES; COHORT STUDIES; DABIGATRAN; FEMALE; HEMORRHAGE; HUMANS; MALE; PERIOPERATIVE PERIOD; POSTOPERATIVE COMPLICATIONS; PRECISION MEDICINE; PROSPECTIVE STUDIES; PYRAZOLES; PYRIDONES; RIVAROXABAN;

EID: 85046284711     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH17-08-0553     Document Type: Article

References (47)

1. Spyropoulos A. C. Al-Badri A. Sherwood M. W. Douketis J. D. Periprocedural management of patients receiving a vitamin K antagonist or a direct oral anticoagulant requiring an elective procedure or surgery. J Thromb Haemost: 2016; 14 05 875 885
2. Heidbuchel H. Verhamme P. Alings M., et al. Advisors. Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J: 2016; ehw058
3. Macle L. Cairns J. Leblanc K., et al. CCS Atrial Fibrillation Guidelines Committee. 2016 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation. Can J Cardiol: 2016; 32 10 1170 1185
4. Douketis J. D. Spyropoulos A. C. Kaatz S., et al. BRIDGE Investigators. Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation. N Engl J Med: 2015; 373 09 823 833
5. Healey J. S. Eikelboom J. Douketis J., et al. RE-LY Investigators. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation: 2012; 126 03 343 348
6. Douketis J. D. Berger P. B. Dunn A. S., et al. The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest: 2008; 133 (6, Suppl): 299S 339S
7. Douketis J. D. Healey J. S. Brueckmann M., et al. Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. Substudy of the RE-LY trial. Thromb Haemost: 2015; 113 03 625 632
8. Narouze S. Benzon H. T. Provenzano D. A., et al. Interventional spine and pain procedures in patients on antiplatelet and anticoagulant medications: guidelines from the American Society of Regional Anesthesia and Pain Medicine, the European Society of Regional Anaesthesia and Pain Therapy, the American Academy of Pain Medicine, the International Neuromodulation Society, the North American Neuromodulation Society, and the World Institute of Pain. Reg Anesth Pain Med: 2015; 40 03 182 212
9. Doherty J. U. Gluckman T. J. Hucker W. J., et al. 2017 ACC Expert Consensus Decision Pathway for Periprocedural Management of Anticoagulation in Patients With Nonvalvular Atrial Fibrillation: a report of the American College of Cardiology Clinical Expert Consensus Document Task Force. J Am Coll Cardiol: 2017; 69 07 871 898
10. Raval A. N. Cigarroa J. E. Chung M. K., et al. American Heart Association Clinical Pharmacology Subcommittee of the Acute Cardiac Care and General Cardiology Committee of the Council on Clinical Cardiology; Council on Cardiovascular Disease in the Young; and Council on Quality of Care and Outcomes Research. Management of patients on non-vitamin K antagonist oral anticoagulants in the acute care and periprocedural setting: a scientific statement from the American Heart Association. Circulation: 2017; 135 10 e604 e633
11. Schulman S. Carrier M. Lee A. Y., et al. Periop Dabigatran Study Group. Perioperative management of dabigatran: a prospective cohort study. Circulation: 2015; 132 03 167 173
12. Siegal D. Yudin J. Kaatz S. Douketis J. D. Lim W. Spyropoulos A. C. Periprocedural heparin bridging in patients receiving vitamin K antagonists: systematic review and meta-analysis of bleeding and thromboembolic rates. Circulation: 2012; 126 13 1630 1639
13. Douketis J. D. Spyropoulos A. C. Spencer F. A., et al. Perioperative management of antithrombotic therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest: 2012; 141 (2, Suppl): e326S e350S
14. Samuelson B. T. Cuker A. Siegal D. M. Crowther M. Garcia D. A. Laboratory assessment of the anticoagulant activity of direct oral anticoagulants: a systematic review. Chest: 2017; 151 01 127 138
15. Van Blerk M. Bailleul E. Chatelain B., et al. Influence of dabigatran and rivaroxaban on routine coagulation assays. A nationwide Belgian survey. Thromb Haemost: 2015; 113 01 154 164
16. Tripodi A. Padovan L. Veena C. Scalambrino E. Testa S. Peyvandi F. How the direct oral anticoagulant apixaban affects thrombin generation parameters. Thromb Res: 2015; 135 06 1186 1190
17. Vandenbroucke J. P. von Elm E. Altman D. G., et al. STROBE Initiative. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med: 2007; 4 10 e297
18. Euser A. M. Zoccali C. Jager K. J. Dekker F. W. Cohort studies: prospective versus retrospective. Nephron Clin Pract: 2009; 113 03 c214 c217
19. Cockcroft D. W. Gault M. H. Prediction of creatinine clearance from serum creatinine. Nephron: 1976; 16 01 31 41
20. Connolly S. J. Ezekowitz M. D. Yusuf S., et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med: 2009; 361 12 1139 1151
21. Granger C. B. Alexander J. H. McMurray J. J., et al. ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med: 2011; 365 11 981 992
22. Patel M. R. Mahaffey K. W. Garg J., et al. ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med: 2011; 365 10 883 891
23. Giugliano R. P. Ruff C. T. Braunwald E., et al. ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med: 2013; 369 22 2093 2104
24. Gladstone D. J. Geerts W. H. Douketis J. Ivers N. Healey J. S. Leblanc K. How to monitor patients receiving direct oral anticoagulants for stroke prevention in atrial fibrillation: a practice tool endorsed by Thrombosis Canada, the Canadian Stroke Consortium, the Canadian Cardiovascular Pharmacists Network, and the Canadian Cardiovascular Society. Ann Intern Med: 2015; 163 05 382 385
25. Spyropoulos A. C. Douketis J. D. How I treat anticoagulated patients undergoing an elective procedure or surgery. Blood: 2012; 120 15 2954 2962
26. Clark N. P. Witt D. M. Davies L. E., et al. Bleeding, recurrent venous thromboembolism, and mortality risks during warfarin interruption for invasive procedures. JAMA Intern Med: 2015; 175 07 1163 1168
27. Skeith L. Taylor J. Lazo-Langner A. Kovacs M. J. Conservative perioperative anticoagulation management in patients with chronic venous thromboembolic disease: a cohort study. J Thromb Haemost: 2012; 10 11 2298 2304
28. Baron T. H. Kamath P. S. McBane R. D. New anticoagulant and antiplatelet agents: a primer for the gastroenterologist. Clin Gastroenterol Hepatol: 2014; 12 02 187 195
29. Witt D. M. Delate T. McCool K. H., et al. WARPED Consortium. Incidence and predictors of bleeding or thrombosis after polypectomy in patients receiving and not receiving anticoagulation therapy. J Thromb Haemost: 2009; 7 12 1982 1989
30. Gage B. F. Waterman A. D. Shannon W. Boechler M. Rich M. W. Radford M. J. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA: 2001; 285 22 2864 2870
31. Lip G. Y. Nieuwlaat R. Pisters R. Lane D. A. Crijns H. J. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest: 2010; 137 02 263 272
32. Steinberg B. A. Peterson E. D. Kim S., et al. Outcomes Registry for Better Informed Treatment of Atrial Fibrillation Investigators and Patients. Use and outcomes associated with bridging during anticoagulation interruptions in patients with atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Circulation: 2015; 131 05 488 494
33. Stangier J. Rathgen K. Stähle H. Gansser D. Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol: 2007; 64 03 292 303
34. Stangier J. Rathgen K. Stähle H. Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet: 2010; 49 04 259 268
35. Kubitza D. Becka M. Wensing G. Voith B. Zuehlsdorf M. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 - an oral, direct Factor Xa inhibitor - after multiple dosing in healthy male subjects. Eur J Clin Pharmacol: 2005; 61 12 873 880
36. Cui Y. Song Y. Wang J., et al. Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects. Clin Pharmacol: 2013; 5 177 184
37. Douketis J. D. Syed S. Schulman S. Periprocedural management of direct oral anticoagulants: comment on the 2015 American Society of Regional Anesthesia and Pain Medicine Guidelines. Reg Anesth Pain Med: 2016; 41 02 127 129
38. Dunn A. S. Spyropoulos A. C. Turpie A. G. Bridging therapy in patients on long-term oral anticoagulants who require surgery: the Prospective Peri-operative Enoxaparin Cohort Trial (PROSPECT). J Thromb Haemost: 2007; 5 11 2211 2218
39. Schulman S. Angerås U. Bergqvist D. Eriksson B. Lassen M. R. Fisher W.; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost: 2010; 8 01 202 204
40. Garcia D. Alexander J. H. Wallentin L., et al. Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures. Blood: 2014; 124 25 3692 3698
41. Sherwood M. W. Douketis J. D. Patel M. R., et al. ROCKET AF Investigators. Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). Circulation: 2014; 129 18 1850 1859
42. Beyer-Westendorf J. Gelbricht V. Förster K., et al. Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry. Eur Heart J: 2014; 35 28 1888 1896
43. Godier A. Martin A. C. Leblanc I., et al. Peri-procedural management of dabigatran and rivaroxaban: Duration of anticoagulant discontinuation and drug concentrations. Thromb Res: 2015; 136 04 763 768
44. Douketis J. Weitz J. Murphy S. A., et al. Perioperative adverse outcomes in patients with atrial fibrillation taking edoxaban or warfarin: Analysis of the ENGAGE AF-TIMI 48 Trial. J Am Coll Cardiol: 2015; 65 (10S): A2092
45. Douketis J. D. Wang G. Chan N., et al. Effect of standardized perioperative dabigatran interruption on the residual anticoagulation effect at the time of surgery or procedure. J Thromb Haemost: 2016; 14 01 89 97
46. Tripodi A. To measure or not to measure direct oral anticoagulants before surgery or invasive procedures. J Thromb Haemost: 2016; 14 07 1325 1327
47. Spyropoulos A. C. Al-Badri A. Sherwood M. W. Douketis J. D. To measure or not to measure direct oral anticoagulants before surgery or invasive procedures: comment. J Thromb Haemost: 2016; 14 12 2556 2559